Cannabics Pharmaceuticals has signed a Memorandum Of Understanding with Cannomed Medical Cannabis Industries, to develop cannabis cultivars targeted to treat cancers of different types.
"The collaboration will allow Cannabics to further expand its portfolio of cannabinoid compositions that will be extracted from Cannomed's 17 unique strains, thus contributing to its compound library matrix," the team with the company explains. "Cannabics will proceed to utilize its High Throughput Screening (HTS) facility in Israel to extract the active ingredients and examine their anti-tumor properties on a variety of human cancer cells of various types."
Cannomed, a publicly traded Israeli company, is a vertically integrated manufacturer and cultivator which holds distribution agreements in regulated markets in Europe. Cannomed cultivates 17 unique cannabis cultivars originating from proprietary genetics developed by the company. These cultivars will be assessed and screened for their anti-tumor potential.
Dr. Eyal Ballan, CTO and Co-Founder of Cannabics Pharmaceuticals said:" Cannomed and Cannabics will collaborate to develop cannabinoid products based on Cannomed's cannabis cultivars. We have seen in the past similar collaborations yielding valuable data in pre-clinical studies held at our facility, and we are looking forward to revealing what anti-tumor potential Cannomed's strains may hold".
Mr. Kfir Gindi, CEO and Co-Founder of Cannomed, said: "We are excited to be able to collaborate with Cannabics Pharmaceuticals to explore the medicinal qualities of our unique genetic proprietary cannabis strains. This will potentially yield the development of cannabis-based products that will eventually be manufactured and distributed in European regulated markets, where Cannomed has distribution agreements".